gestonorone-caproate and Adenocarcinoma

gestonorone-caproate has been researched along with Adenocarcinoma* in 6 studies

Trials

1 trial(s) available for gestonorone-caproate and Adenocarcinoma

ArticleYear
Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion.
    Tumori, 1983, Feb-28, Volume: 69, Issue:1

    A pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion was carried out. All patients received total abdominal hysterectomy and bilateral salpingo-oophorectomy plus complementary radium therapy on the vaginal stump. After the conventional treatment, patients were randomly allocated to adjuvant hormone therapy or no further treatment. Hormone therapy consisted of gestonorone caproate (17 alpha-hydroxy-19-norpregn-4-en 3, 20 dione caproate) administered i.m. at the dose of 200 mg/week for 1 year. Of the 62 patients who entered the study, 51 were considered evaluable (24 with adjuvant hormone therapy and 27 with no further treatment). Five patients had a relapse: four of these were in the group with no further treatment. Actuarial relapse-free survival analysis at 5 years was 95.7% in the group of adjuvant-treated patients and 82.8% in the control group. Although there is no statistical significance, adjuvant therapy appears to result in an increase in relapse-free survival in the group of patients with deep myometrial invasion and undifferentiated carcinoma. Further studies are necessary to assess the effectiveness of hormone adjuvant treatment in FIGO stage I endometrial carcinoma with myometrial invasion.

    Topics: Adenocarcinoma; Aged; Castration; Fallopian Tubes; Female; Gestonorone Caproate; Humans; Hysterectomy; Middle Aged; Pilot Projects; Radium; Uterine Neoplasms

1983

Other Studies

5 other study(ies) available for gestonorone-caproate and Adenocarcinoma

ArticleYear
In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy.
    Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:1

    As previously reported, ovarian epithelial carcinomas may respond to endocrine therapy. We examined the direct effect of progesterone, medroxyprogesteroneacetate, gestoneron, 17-beta-estradiol, tamoxifen, 4-OH-tamoxifen, or N-desmethyltamoxifen on the proliferative capacity of ovarian carcinoma cells by means of the colony assay described by Hamburger and Salmon. The growth rate of 25 tested tumors (ascitic fluid, primary tumor, metastases) was 68%. The plating efficiency was 0.078%. Beside the drug testing estrogen and progesterone receptor levels were determined. The inhibition of colony survival was slightest with 17-beta-estradiol, more pronounced with medroxyprogesteroneacetate, gestoneron, N-desmethyltamoxifen, and progesterone, and greatest with 4-OH-tamoxifen and tamoxifen. Significant and dose-dependent inhibition of greater than 70% was observed with tamoxifen and 4-OH-tamoxifen in 80% of the tested tumors. There was no significant correlation between the in vitro responsiveness and the level of hormonal act not only via an estrogen receptor but also via an antiestrogen-binding site.

    Topics: Adenocarcinoma; Aged; Cell Division; Cells, Cultured; Estradiol; Estrogen Antagonists; Ethanol; Female; Gestonorone Caproate; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Ovarian Neoplasms; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen

1986
Use of progestogens as an adjuvant to surgery in the treatment of stage I adenocarcinoma of the uterine corpus.
    British journal of obstetrics and gynaecology, 1983, Volume: 90, Issue:2

    Fifty-nine patients with proven stage I adenocarcinoma of the uterine corpus were treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, followed by gestronal hexanoate intramuscularly for 3 months and then medroxyprogesterone acetate orally for a prolonged period. In the 7-year period of study, there were no vaginal recurrences, but one patient suffered a recurrence in the inguinal lymph nodes and pelvis. Undesirable side effects did not occur. These results compare favourably with other reported studies in which surgery and radiotherapy were used.

    Topics: Adenocarcinoma; Adult; Aged; Castration; Female; Gestonorone Caproate; Humans; Hysterectomy; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Postoperative Period; Recurrence; Uterine Neoplasms

1983
Progestogen therapy for ovarian carcinoma.
    British journal of obstetrics and gynaecology, 1982, Volume: 89, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Female; Gestonorone Caproate; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Ovarian Neoplasms

1982
On gestagen treatment of advanced prostatic carcinoma.
    Scandinavian journal of urology and nephrology, 1978, Volume: 12, Issue:2

    Depostat treatment was found to reduce plasma testosterone and to have a gonadotrophin suppressive effect in males. In our study the clinical effect on prostatic cancer was, however, disappointing when compared to the well established effect of orchiectomy. The therapeutic failure of Depostat might be related to the incomplete suppression of plasma testosterone compared to that observed after orchiectomy.

    Topics: Adenocarcinoma; Aged; Castration; Drug Evaluation; Gestonorone Caproate; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone

1978
The influence of the progestogen gestonorone caproate on testosterone turnover in renal cell carcinoma. An in vitro study.
    Investigative urology, 1976, Volume: 13, Issue:4

    To investigate the effect of gestagens on renal cell carcinoma 300-mg slices of normal, human kidney, renal cell carcinoma (RCC), and preoperatively irradiated RCC were subjected to a short term incubation with 200 pmoles of 3H-testosterone and 1 and 2 mug of gestonorone caproate. In the normal kidney 61.4 per cent of the testosterone added was metabolized, the oxidation products androstenedione and epitestosterone outweighing by 6:1 the reduction products 5alpha-dihydrotestosterone and androstanediol. In RCC only 22 per cent of the testosterone was metabolized, with 8.5 per cent being converted to 5alpha-androstanes. Gestonorone caproate essentially did not influence testosterone turnover. This can be explained by its action as an inhibitor of the reductive pathway of the testosterone metabolism only, which is insignificant in these tissues.

    Topics: Adenocarcinoma; Gestonorone Caproate; Humans; Kidney; Kidney Neoplasms; Oxidation-Reduction; Testosterone

1976